Tong et al. 2026

Improved Prediction of Vancomycin Pharmacokinetics in Patients Receiving Continuous Renal Replacement Therapy Using a Novel Population Model Validated With Real-World Data

Therapeutic Drug Monitoring · 10.1097/FTD.0000000000001432

Structure

A two-compartment model, driven by weight, age and serum creatinine.

Study population

General patients — United States and North America. Fitted to 2,409 patients and 7,264 concentration observations.

Covariate As reported
Age 62 (18–100) yr
Weight 89 (28–350) kg
BMI 30 (13–69.6) kg/m²
CrCl 61 (3.1–930) mL/min
SCr 1.5 (0.1–33) mg/dL

Reported as the source publication gives them — mean ± SD, or median with range or interquartile range.

Equations

The model's structural parameters as Chorus implements them.

CLrenal=4.225(FFM70)0.75(AGE55)0.4(eGFRCKDEPI100)0.841CL_{renal} = 4.225 \cdot \left(\frac{FFM}{70}\right)^{0.75} \cdot \left(\frac{AGE}{55}\right)^{-0.4} \cdot \left(\frac{eGFR_{CKD-EPI}}{100}\right)^{0.841}V1=72.973(FFM70)0.6V_1 = 72.973 \cdot \left(\frac{FFM}{70}\right)^{0.6}V2=46.306(FFM70)0.6V_2 = 46.306 \cdot \left(\frac{FFM}{70}\right)^{0.6}Q=2.438(FFM70)0.75Q = 2.438 \cdot \left(\frac{FFM}{70}\right)^{0.75}
LaTeX source
CL_{renal} = 4.225 \cdot \left(\frac{FFM}{70}\right)^{0.75} \cdot \left(\frac{AGE}{55}\right)^{-0.4} \cdot \left(\frac{eGFR_{CKD-EPI}}{100}\right)^{0.841}
V_1 = 72.973 \cdot \left(\frac{FFM}{70}\right)^{0.6}
V_2 = 46.306 \cdot \left(\frac{FFM}{70}\right)^{0.6}
Q = 2.438 \cdot \left(\frac{FFM}{70}\right)^{0.75}

Implementation notes

Model developed with CRRT parameters; implemented here for non-RRT patients (CL_CRRT excluded).

Simulation settings

Models

selected

Dose candidates (mg)

Interval candidates (h)

Demographics

Physical characteristics.

kg
cm
yr